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The tumor suppressor p53 is one of the most 
extensively studied proteins (1, 2). At the cellu-
lar level, p53 acts as a “gatekeeper” to eliminate 
potentially tumorigenic cells by in  ducing pro-
grammed cell death, inhibiting the proliferation 
of damaged cells through cell cycle arrest (3), or 
inducing cells to withdraw from the cell cycle, 
referred to as cellular senescence (4, 5). The abil-
ity of p53 to induce apoptosis is considered the 
primary means by which p53 suppresses tumor 
growth (6–9). However, experiments have shown 
that p53 defi  ciency does not necessarily translate 
into an interruption in the apoptotic response 
(10, 11). We hypothesize that the ability of p53 to 
induce cell cycle arrest or senescence, in some cases, 
could play a central role in tumor suppression.
At the molecular level, activated p53 func-
tions as a transcription factor by transactivating 
genes that are important for inducing apopto-
sis or cell cycle arrest and senescence (12, 13). 
Therefore, gene expression profi  les can be used 
as markers of apoptosis or senescence. The   levels 
of proapoptotic proteins, such as p53-upregulated 
modulator of apoptosis (PUMA), are elevated in 
cells programmed to undergo apoptosis (14, 15), 
whereas the cyclin-dependent kinase (CDK) inhi-
bitor p21, a well-studied downstream target of 
p53, is highly expressed in cells undergoing cell 
cycle arrest and senescence. p21 directly inhibits 
CDK2 and plays a   pivotal role in p53-induced 
cell cycle arrest (16). It is also an important 
molecule in one of the mechanisms leading to 
senescence (17).
The term senescence refers to the fi  nite 
replicative lifespan of cultured human cells that 
enter a stable growth-arrested state (18). Cur-
rently, senescence is recognized as the fi  nal 
phenotypic state adopted by a cell in response 
to various stimuli. Senescent cells show a char-
acteristic fl  attened and enlarged morphology and 
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are positive for acidic β-galactosidase (β-gal) activity (19). 
Senescent cells also undergo dramatic chromatin remodeling 
and express proteins that are characteristic of transcriptionally 
silent heterochromatin. An example of these proteins is the 
heterochromatin protein 1 (HP1) family member HP1γ, which 
has been established as a marker for senescence-associated 
  heterochromatin foci (SAHF) (20) in human (21) and murine 
cells (22). Numerous studies suggest that a major cause of 
  senescence in human cells is telomeric shortening (23), which 
triggers cellular responses that are identical in many aspects to 
a DNA damage response (24, 25). Additionally, DNA damage 
could be considered an extrinsic factor contributing to cellu-
lar senescence. Because of its essential property of cell growth 
arrest, senescence is proposed as a potent tumor suppressor 
mechanism (26).
DNA damage occurs in the developing lymphocytes 
when these cells begin to rearrange antigen receptor genes in 
a process termed V(D)J recombination. This genetically pro-
grammed DNA rearrangement process involves the cleavage 
of DNA double-strands at the recombination signal sequences 
by the Rag nucleases, which generate two kinds of DNA 
breaks—signal ends and coding ends (27). Signal ends are 
blunt and 5′-phosphorylated, whereas coding ends are cova-
lently sealed to form a hairpin structure requiring further pro-
cessing by the DNA-dependent protein kinase (DNA–PK) 
and the repair factor Artemis complex before ligation (28). 
Both signal and coding ends are joined by the nonhomolo-
gous end-joining (NHEJ), which is a major DNA repair 
pathway that is generally responsible for the repair of DNA 
double-strand breaks (DSBs). The participating factors in this 
pathway are the DNA–PK complex, which includes the 
DNA-binding subunits Ku70 and Ku80 and the catalytic 
subunit of DNA–PK, the repair factor Artemis, and the DNA 
ligase complex, which is composed of DNA ligase IV, 
XRCC4, and XLF/Cernunnos (29, 30). All of the NHEJ 
factors are essential for V(D)J recombination; a severe com-
bined immunodefi   cient phenotype results from impaired 
V(D)J recombination in mice defi  cient in each of the joining 
factors (31, 32).
In NHEJ-defi   cient mice, Rag-mediated DNA breaks 
accu  mulate because the breaks cannot be joined by other 
nonspecifi  c end-joining activity. However, the stalled V(D)J 
recombination breaks induce a p53-dependent apoptosis in 
developing lymphoid cells. Therefore, NHEJ-defi  cient mice 
do not usually develop early lymphomas. In contrast, Rag-
mediated DSBs lead to massive genomic instability in the ab-
sence of both p53 and NHEJ activity, including chromosomal 
translocations and oncogenic gene amplifi  cations (33, 34). As 
a result, double-null mice succumb to early pro-B lymphomas 
with chromosomal translocation at chromosome 12 at the 
  immunoglobulin locus and chromosome 15 near the protoon-
cogene c-Myc. The involvement of Rag nucleases in tumorigen-
esis has been confi  rmed by the lack of lymphoma development 
in Rag, NHEJ, and p53 triple-defi  cient mice (35, 36).
A unique p53 mutation, p53R175P (the human equivalent 
of murine R172P), which was originally identifi  ed from 
  human tumor samples (37, 38), provides an excellent model 
to study the role of p53-dependent cell cycle arrest and senes-
cence in tumor suppression. Although p53R175P lacks the 
ability to induce apoptosis in response to various stimuli, it 
retains its partial ability to induce cell cycle arrest through its 
ability to transactivate key molecules such as the CDK inhib-
itor p21 (10, 37). In this study, we crossed NHEJ-defi  cient 
mice into a p53R172P mutant background to establish an in 
vivo model to examine the involvement of the p53–p21 
pathway in the induction of cell cycle arrest and senescence 
in response to DNA damage and the consequent suppression 
of genomic instability and tumorigenesis.
RESULTS
Mutant p53R172P rescues embryonic lethality caused by DNA 
ligase IV defi  ciency and suppresses tumorigenesis
To determine whether the p53R172P mutant was suffi   cient to 
suppress tumorigenesis, we crossed heterozygous DNA ligase 
IV–defi  cient mice (Lig4+/−) with p53R172P/R172P mice (p53p/p) 
to generate Lig4+/− p53+/p mice. These animals were subse-
quently interbred to generate Lig4+/− p53p/p mice, which 
were viable and fertile. Next, Lig4−/− p53p/p mice were gen-
erated from crossing Lig4+/− p53p/p mice. 24% (67 out of 
279) of pups from the Lig4+/− p53p/p breeding were geno-
typed as Lig4−/− p53p/p (Table S1, available at http://www
.jem.org/cgi/content/full/jem.20062453/DC1). This num-
ber was very close to the expected Mendelian segregation 
ratio. This indicates that the mutant p53R172P successfully res-
cued the embryonic lethality caused by the DNA ligase IV 
defi  ciency, and the embryonic lethality of Lig4−/− was caused 
by p53-dependent apoptosis (39, 40). Similar to Lig4−/− 
p53−/− mice (Fig. S1), Lig4−/− p53p/p mice were smaller 
than their Lig4+/− or Lig4+/+ littermates (Fig. 1 A). 6 out of 
25 Lig4−/− p53p/p mice died shortly after weaning. These 
mice had diffi   culty ingesting solid food, and the necropsy 
of a 4-wk-old Lig4−/− p53p/p mouse revealed the cause of 
death was starvation and not tumor-related (unpublished data). 
Figure 1.  Phenotype, survival curve, and lymphoma incidence. 
(A) Lig4−/− p53p/p (top) and Lig4+/− p53p/p (bottom) mice. (B) Survival curve 
of Lig4−/− p53p/p mice (black) and Lig4−/− p53−/− mice (red). Lig4−/− 
p53p/p survival is signifi  cantly different from Lig4−/− p53−/− mice (P = 
0.000204 by log rank test). (C) Lymphoma incidence in Lig4−/− p53p/p and 
Lig4−/− p53−/− mice.JEM VOL. 204, June 11, 2007  1455
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  After the malnourishment problem was corrected by simply 
providing soft food, all Lig4−/− p53p/p mice survived far 
  beyond the weaning age and signifi  cantly longer than the 
Lig4−/− p53−/− mice (Fig. 1 B; P < 0.001, log rank test). 
The median survival age of Lig4−/− p53p/p mice was  120 d, 
compared with 65 d for the Lig4−/− p53−/− mice. Of partic-
ular note, 2 of the mice survived beyond 6 mo of age (Fig. 
1 B), which was never observed in Lig4−/− p53−/− mice. 
Remarkably, Lig4−/− p53p/p mice were free of lymphomas 
and any other types of tumor, whereas 14 out of 15 Lig4−/− 
p53−/− mice died of pro-B lymphomas (Fig. 1, B and C; one 
Lig4−/− p53−/− mouse died around the weaning age with 
enlarged incisor teeth). These results clearly demonstrated that 
the p53R172P mutation successfully rescued the embryonic 
lethality of Lig4-defi  cient mice and suppressed the develop-
ment of lymphomas in Lig4−/− p53p/p mice.
In the absence of apoptosis, Lig4−/− p53p/p precursor 
lymphocytes enter senescence
To confi  rm the defective apoptosis in p53R172P mice, we per-
formed a TUNEL assay and a hematoxylin and eosin (HE) 
staining of thymic sections from Lig4−/− p53p/p, Lig4−/− p53−/−, 
and NHEJ-defi  cient mice (Artemis−/−). As   predicted, apopto-
sis was not observed in thymic sections from Lig4−/− p53−/− 
or Lig4−/− p53p/p mice, whereas apoptosis was   readily detected 
in thymic sections from Artemis−/− mice (Fig. S2, available 
Figure 2.  Developing lymphoid cells undergo senescence. β-gal 
staining for thymic sections (A) and bone marrow cells (B) of Lig4−/− 
p53p/p, Lig4−/− p53−/−, and Lig4+/+ p53p/p mice showing positive staining 
only in Lig4−/− p53p/p mice. Anti-HP1γ staining of thymic sections (C) and 
bone marrow cells (D) of Lig4−/− p53p/p, Lig4−/− p53−/−, and Lig4+/+ p53p/p 
mice; positive staining was observed only in Lig4−/− p53p/p mice. (E) Bone 
marrow cells from Lig4−/− p53p/p mice, positive for β-gal staining, 
were costained with the B cell marker CD19 (dark brown cells); arrows 
show double-positive cells and an example of bone marrow cells from 
Lig4−/− p53p/p mice that are positively stained for CD19 and HP1γ (F), 
showing single channel of green fl  uorescence (HP1), red (CD19) and blue 
(DAPI), and merged image; (G) thymocytes staining positive for HP1γ 
(green), CD25 (red), and DAPI (blue). Images with wider views of both 
stainings are shown in Figs. S5 and S6, available at http://www.jem.org/
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at http://www.jem.org/cgi/content/full/jem.20062453/DC1). 
These results confi  rmed that Rag-mediated DNA DSBs in-
duce a p53-dependent apoptosis in NHEJ-defi  cient mice, 
but is completely absent in the p53R172P mutant background. 
HE staining of thymic sections from Lig4−/− p53p/p mice 
showed decreased cellular density compared with wild-type 
(WT) and Lig4−/− p53−/− mice (Fig. S3), but the density was 
similar to that of Artemis−/− mice. In addition, the cellularity 
of thymus from a 4-wk-old Lig4−/− p53p/p mouse is only 1.3 
million cells, compared with 202 million cells from a Lig4+/+ 
p53p/p littermate. Analysis by fl  ow cytometry indicated a 
  severe developmental blockage in both thymocytes and bone 
marrow cells at early stages (Fig. S4). This confi  rms that the 
mutant p53R172P is not capable of rescuing V(D)J recombina-
tion, but is able to inhibit tumorigenesis in developing lymphoid 
cells, possibly by responding to the V(D)J recombination–
associated breaks and inhibiting genomic instability.
Given that cellular senescence is proposed to be an anti-
cancer mechanism (4), we thought the Lig4−/− p53p/p mice 
served as an excellent in vivo model for investigating this 
potential antitumor activity. To determine whether the mu-
tant p53R172P protein was able to induce senescence in re-
sponse to Rag-mediated DNA breaks, lymphoid cells from 
Lig4−/− p53p/p mice were examined using the senescence-
associated acidic β-gal assay. β-gal staining of thymic sections 
revealed a large number of Lig4−/− p53p/p thymocytes had 
entered a senescent state, whereas no β-gal–positive thymo-
cytes were observed in Lig4+/+ p53p/p littermates or age-
matched Lig4−/− p53−/− mice (Fig. 2 A). Because Lig4−/− 
p53−/− mice succumb to pro-B lymphomas at an early age 
(35), we examined the extent to which cellular senescence 
occurs in developing B lymphocytes. Bone marrow cells 
were isolated and stained for β-gal activity. As shown in Fig. 
2 B, bone marrow cells from Lig4−/− p53p/p, but not cells 
from Lig4+/+ p53p/p littermates or age-matched Lig4−/− 
p53−/− mice, were stained positive for β-gal. Furthermore, 
similar results were obtained when thymic sections (Fig. 2 C) 
and bone marrow cells (Fig. 2 D) were stained with HP1γ, 
which is a diff  erent marker for senescence. To verify that 
these β-gal–positive bone marrow cells were precursor B 
cells, the cells were also stained with the anti-CD19 surface 
marker. The results revealed that most of the β-gal–positive 
cells were, indeed, CD19 positive (Fig. 2 E), thereby con-
fi  rming their B cell lineage. Similarly, HP1γ-positive cells in 
the bone marrow and thymus of Lig4−/− p53p/p were also 
stained positive for the surface markers CD19 and CD25, re-
spectively (Fig. 2, F and G; and Figs. S5 and S6, available at 
http://www.jem.org/cgi/content/full/jem.20062453/DC1) 
and HP1γ staining was not detected in Lig4−/− p53−/− thy-
mocytes (Fig. S5). These results indicate that both Lig4−/− 
p53p/p T and B precursor lymphoid cells undergo senescence 
in a p53-dependent pathway. This strongly suggests that un-
repaired Rag-mediated DSBs are able to activate p53R172P 
and that its residual activity is suffi   cient to induce senescence, 
which successfully blocks tumorigenesis in the lymphoid 
precursor cells.
Accumulation of aberrant V(D)J recombination breaks 
in Lig4−/− p53p/p thymocytes
Cleavage of DNA by the Rag nucleases generates blunt signal 
ends and hairpin coding ends. Signal ends are protected in the 
postcleavage complex and are persistent in WT lymphoid 
precursor cells (41), whereas hairpin coding ends are usually 
resolved rapidly. As a result, coding ends never accumulate in 
WT mice. However, hairpin coding ends were previously 
detected in the thymocytes of DNA–PKcs–defi  cient, Artemis-
defi  cient, and Ku80-defi  cient mice (42–44) because of a 
defect in processing and opening the hairpins. Because DNA 
ligase IV functions in the last step of V(D)J recombination 
end joining, we tested whether coding ends, either hairpin or 
open-end forms, were present in the Lig4−/− p53p/p lym-
phoid cells. Coding ends have been previously detected by 
the ligation-mediated PCR (LMPCR) assay (45, 46), which 
is the same methodology used in this study. Our LMPCR 
assay revealed that signal ends were clearly present at the 
TCR Dδ2 site in WT and Lig4−/− p53p/p samples (Fig. 3, A 
and B). ApaLI digestion cut the perfect signal ends and 
reduced the fragment size from 123 bp to 98 bp (Fig. 3 B, 
left). However, in Lig4−/− p53p/p, but not in WT thymocytes, 
DNA breaks in addition to the signal ends were clearly de-
tected. These were potential coding ends. This was further 
demonstrated by the increased intensity of bands in those 
DNA samples treated with DNA polymerase or mung bean 
nuclease. Because LMPCR assays can only detect DNA breaks 
with open blunt termini, treatment with DNA polymerase 
Figure 3.  Accumulation of open coding ends in Lig4−/− p53p/p 
thymocytes. (A) Diagram of V(D)J recombination activity at the TCRδ 
locus. Cleavage by Rag nucleases generates a blunt signal end (se) and 
hairpin coding end (ce), which can be further processed by the DNA–PK–
Artemis complex. (B) LMPCR assay of WT and Lig4−/− p53p/p (LP) thymo-
cytes, signal ends can be digested by ApaLI to reduce the PCR products 
from 123 to 98 bp. The residual species are coding ends, which was con-
fi  rmed by cloning and sequencing (Fig. S6). MBN, mung bean nuclease; 
T4 Pol, T4 DNA polymerase. Fig. S6 is available at http://www.jem.org/
cgi/content/full/jem.20062453/DC1.JEM VOL. 204, June 11, 2007  1457
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(which does not open hairpin coding ends) converts those 
ends with single-strand overhangs to blunt ends. On the 
other hand, mung bean nuclease opens the hairpin ends, thus 
allowing the detection of these sealed ends. Our results re-
vealed that both treatments enhanced the extent to which 
potential coding ends were detected, suggesting the presence 
of coding ends with a single-strand overhang and hairpin 
ends. This is the fi  rst report of the direct detection of pro-
cessed (open) coding ends in the mouse, mechanistically im-
plicating a stepwise processing of hairpin coding ends by the 
DNA–PKcs–Artemis complex.
To confi  rm that these ends were coding ends, we cloned 
and sequenced the PCR products that were resistant to ApaLI 
digestion. Three individual PCRs of the DNA polymerase-
treated samples were performed, and the products were 
cloned into Escherichia coli and screened for ApaLI-resistant 
colonies. Sequencing analyses revealed that these were in-
deed coding ends. We found perfect coding ends containing 
the entire Dδ2 coding sequences, as well as coding ends with 
3–6 nucleotide deletions (Fig. S7, available at http://www
.jem.org/cgi/content/full/jem.20062453/DC1). Our results 
indicate that in Lig4 defi  ciency, Rag-liberated hairpin coding 
ends cannot be joined, but they can still be processed by the 
DNA–PK and Artemis complex. However, whereas aberrant 
ends normally induce a p53-dependent DNA damage re-
sponse that leads to apoptosis, these ends instead induce mu-
tant p53 response in Lig4−/− p53p/p mice that drives cells 
with these aberrant ends to undergo cell cycle arrest and be-
come senescent.
Euploid profi  le of Lig4−/− p53p/p cells with limited 
chromosomal breaks
Our previous study conducted in NHEJ/p53−/− mice indi-
cated that Rag-mediated DSBs formed during V(D)J recom-
bination and, if not properly controlled during the cell cycle, 
lead to genomic instability and tumorigenesis (35). Because 
Lig4−/− p53p/p mice do not succumb to lymphomas, we 
compared the extent of genomic instability in precursor 
  lymphoid cells from these two genotypic backgrounds. To 
ensure a fair comparison, liver cells from newborn mice of 
both genotypes before the onset of tumors were examined. 
50 metaphases were analyzed in cells of each genotype; typi-
cal metaphase spreads with telomeric probes are shown in 
Fig. 4 (A and B). Each chromosomal spread was examined 
using confocal microscopy to identify telomeric signals. A 
chromosomal arm without a telomeric signal was scored as a 
chromatid break (47). Most of the Lig4−/− p53p/p metaphases 
contained one or two chromatid breaks, and the majority 
of metaphases were euploid (46 out of 50 metaphases had 
the normal 40 chromosomes). In contrast, Lig4−/− p53−/− 
metaphase spreads predominantly had one or two chromo-
somal breaks, and only 7 out of 50 metaphases (14%) had a 
normal number of chromosomes (Fig. 4, C and D). These re-
sults suggest that aberrant V(D)J recombination breaks result 
in chromatid breaks in cells of each genotype. However, 
the eff  ects of these breaks diff  er between the two   diff  erent 
genotypes; in the absence of the tumor suppressor p53, these 
breaks lead to genomic instability and the activation of onco-
genes, possibly via abnormal chromosomal replication related 
to aneuploidy. In contrast, the mutant p53R172P induces cell 
cycle arrest and senescence, which is suffi   cient to block 
  genomic instability and inhibit tumorigenesis. These results 
underscore the important role of abnormal chromosomal/
centromere duplication in tumorigenesis by inducing chro-
mosomal translocation and amplifi  cation under the eff  ect of 
p53 defi  ciency.
DNA damage response in Lig4−/− p53p/p thymocytes: 
stabilized mutant p53 and activation of p21 protein leads 
to cell cycle arrest and senescence
To understand the p53 activation occurring in Lig4−/− p53p/p 
mice, thymocytes were harvested and examined for the ex-
pression of the mutant p53 by Western blot analysis. A sig-
nifi  cant increase in the p53R172P protein level was observed 
in Lig4−/− p53p/p thymocytes (Fig. 5, lane 2). This p53 level 
was comparable to that observed in Lig4+/+ p53p/p and WT 
thymocytes after irradiation (Fig. 5, lanes 3 and 5), indicating 
that p53R172P could be activated and stabilized in the same way 
as WT p53 in response to DNA damage. The expression of p53 
was not increased in nonirradiated Lig4+/+ p53p/p thymocytes 
(Fig. 5, lane 4), suggesting that V(D)J recombination inter-
mediates, which persist only in thymocytes of Lig4−/− p53p/p 
(Fig. 3 B), induced an elevation in mutant p53   levels. The 
elevated p53 protein level in the Lig4−/− p53p/p thymocytes was 
Figure 4.  Analysis of genomic instability in mouse fetal liver cells. 
Typical chromosomal spreads from Lig4−/− p53p/p (A) and Lig4−/− p53−/− 
(B) newborn liver cells. (C) Abnormal chromosomal count was observed in 
a total of 50 metaphases from 3 different Lig4−/− p53−/− (red column) 
and 9 different Lig4−/− p53p/p mice (blue column); and (D) chromosomal 
breaks in Lig4−/− p53−/− cells (red column) and Lig4−/− p53p/p mice (blue 
column). Numbers in A and B represent chromosome counts only. The 
inset in A shows a typical normal chromosome with 4 telomeric signals 
and a chromosome with a missing telomeric signal. 1458  SENESCENCE SUPPRESSES TUMORIGENESIS | Van Nguyen et al.
also confi  rmed by immunohistochemistry (Fig. S8, available 
at http://www.jem.org/cgi/content/full/jem.20062453/DC1). 
We conclude from our fi  ndings that the p53R172P is able to 
respond to DNA damage, including V(D)J recombination-
associated DSBs, and become activated similarly to the WT p53, 
despite the mutation at R172P.
Next, we assessed whether stabilization of the mutant p53 
could activate the normal p53 downstream eff  ectors. First, we 
examined the level of p21 expression, which is a key factor in 
p53-dependent cell cycle arrest and senescence. Western blot 
analysis revealed that p21 was drastically elevated in Lig4−/− 
p53p/p thymocytes (Fig. 5, lane 2); this was also clearly observed 
in the results of immunohistochemistry (Fig. S9, available at 
http://www.jem.org/cgi/content/full/jem.20062453/DC1). 
This was surprising because a previous study has shown that 
the p53R172P mutant has a partial defect in its ability to activate 
p21 (10). We ruled out the possibility of p53-independent 
activation of p21 because no increase was observed in Lig4−/− 
p53−/− cells (Fig. 5, lane 1). The higher level of p21 observed 
in Lig4−/− p53p/p mice may result from the persistence of 
DSBs that maintain a high level of mutant p53, which still 
possesses a residual ability to transactivate p21. On the other 
hand, the level of the proapoptotic protein PUMA was not 
increased in Lig4−/− p53p/p or Lig4−/− p53−/− mice (Fig. 5 B, 
lanes 2 and 1), which contrasts with the increased level of 
this protein in WT thymocytes (Fig. 5 B, lane 5) undergoing 
apoptosis after irradiation (48). This result was consistent with 
the absence of apoptosis in Lig4−/− p53p/p thymocytes. To-
gether, our results indicate that the V(D)J recombination–
related DSBs induce an elevation in the level of p53R172P, 
which lacks the ability to induce the apoptotic pathway, pos-
sibly caused by a defect in transactivating proapoptotic genes 
such as PUMA and BAX (38, 49). Instead, the mutant p53 
transactivates a high level of p21, which subsequently causes 
cells to enter cell cycle arrest and become senescent.
Although it is well established that p53 is a key factor 
in inducing senescence in response to DNA damage, other 
pathways may also lead to cell senescence independent of p53 
(50, 51). One key molecule in this mechanism is p16INK4a 
(50), which is a positive regulator of the tumor suppressor 
retinoblastoma protein (pRB) and causes cells to senesce in 
response to certain stimuli. To determine whether this path-
way might mediate cellular senescence induced by DNA 
DSBs in this in vivo system, we examined the expression 
levels of p16INK4a and pRB in Lig4−/− p53p/p thymocytes. 
Western blot analysis showed a very low level of the p16INK4a 
in Lig4−/− p53p/p, Lig4+/+ p53p/p, and WT thymocytes, 
eliminating p16INK4a as the factor inducing senescence in 
our system (Fig. S10, available at http://www.jem.org/cgi/
content/full/jem.20062453/DC1). To further rule out any 
involvement of this pathway, Western blot analysis did not 
show any change in the expression of the pRB protein in 
Lig4−/− p53p/p thymocytes compared with WT and Lig4+/+ 
p53p/p thymocytes (Fig. S11). Thus, although the p16–pRB 
pathway may induce senescence in some instances, V(D)J 
recombination breaks mainly induce a p53–p21 pathway 
in Lig4−/− p53p/p thymocytes that in turn, cause the cells to 
enter senescence.
D  I  S  C  U  S  S  I  O  N 
In this study, we have successfully established and character-
ized an in vivo model showing that the mutant p53R172P in-
duces cell cycle arrest and senescence, rather than apoptosis, 
most likely through a p21-dependent pathway in response to 
persistent DNA damage. This response is suffi   cient to inhibit 
genomic instability and suppress tumorigenesis. We report 
for the fi  rst time the detection of aberrant V(D)J recombination 
intermediates (open coding ends) in thymocytes of Lig4−/− 
p53p/p mice. We also detected stabilized mutant p53 and high 
level of p21 in thymocytes, which coincides with large num-
bers of senescent cells in CD25-positive (DN) thymocytes 
and CD19-positive bone marrow cells. Consistent with the 
fi  nding of senescence in precursor lymphoid cells, we found 
a very low level of the proapoptotic protein PUMA in thy-
mocytes. In addition, cytogenetic analysis of the lymphoid 
cells of Lig4−/− p53p/p mice showed normal chromosomal 
counts with few chromosomal breaks, suggesting that the 
p53–p21 pathway was able to suppress genomic instability 
and inhibit tumorigenesis. This was unexpected, taking into 
consideration a previous study in which DNA ligase IV–p53 
double-defi  cient mice succumbed to aggressive pro-B cell 
lymphomas in a Rag-dependent manner, with chromosomal 
translocation and oncogenic amplifi  cation (35).
Based on the fi  ndings of this study in Lig4−/− p53p/p 
mice, we propose the model shown in Fig. 6. When V(D)J 
recombination–induced DSBs remain unrepaired as a result 
of a defi  ciency in the NHEJ pathway, p53 is activated, lead-
ing to apoptosis. In the absence of p53 activity, these DSBs 
induce genomic instability and lymphomagenesis. However, 
when the p53 gene contains the R172P mutation, this same 
DNA damage signal produces a very diff  erent outcome. Cells 
with persistent DSBs induce activation of mutant p53 and, 
subsequently, increase the level of the CDK inhibitor p21 
that causes cells to undergo cell cycle arrest and, ultimately, 
senescence; this is suffi   cient to inhibit tumorigenesis. In addi-
tion, a very low level of proapoptotic protein PUMA was 
Figure 5.  Induction of p53, p21, and PUMA proteins in response 
to DSBs. p53p/p and WT thymocytes exposed to IR (5 Gy), and nonir-
radiated Lig4−/− p53−/− and Lig4−/− p53p/p thymocytes were analyzed 
by Western blotting, using antibodies against p53 and β-actin and p21, 
PUMA, and β-actin.JEM VOL. 204, June 11, 2007  1459
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found in the Lig4−/− p53p/p thymocytes, which is consistent 
with previous studies of the inability of the mutant p53 pro-
tein to transactivate another crucial proapoptotic protein, 
BAX (38, 49). We suggest the inability of p53R172P to acti-
vate apoptosis-related genes explains at least partially why 
the p53R172P mice are defi  cient in apoptosis, confi  rming the 
essential function of the transactivation activity of p53 in 
  inducing apoptosis. Our results also implicate the critical 
role of p53 in determining cell cycle arrest versus apoptosis, in 
addition to the upstream signaling. It is intriguing, however, 
that the mutant p53 is able to transactivate p21 to a very 
high level. Previous studies have indicated that p53R175P 
was able to activate p21 in irradiated cells, but at a reduced 
rate (10, 37, 38). Although we cannot discard the possibility 
that p53R172P may function independently of p21 in pre-
venting genomic instability, it is improbable because we ob-
served increased levels of both p53 and p21 in only Lig4−/− 
p53p/p lymphoid cells, and because recent evidence showed 
that p21 defi  ciency accelerates the tumor onset and chromo-
somal aberrations in p53p/p mice (52). We interpret a high 
p21 level found in Lig4−/− p53p/p thymocytes as likely caused 
by a combination of persistent unrepaired DNA breaks re-
sulting from the defi  ciency of DNA ligase IV and the failure 
of p53 to transactivate other eff  ector genes key to inducing 
apoptosis, such as PUMA and BAX (38). Perhaps this activa-
tion of p21 serves as a “backup” pathway in the event that 
the primary goal, apoptosis, cannot be achieved. Another 
possibility is the accumulation of senescent cells with high 
levels of p21 to maintain their senescent status in thymus and 
bone marrow.
Our previous study of mice with the Lig4−/− p53−/− 
  genotype convincingly demonstrated that the tumorigenic 
process requires chromosomal translocation and rounds of rep-
lication to amplify the oncogene c-Myc by means of   breakage–
fusion–bridge cycles (35). In this study, our data suggest that 
in the absence of an apoptosis pathway, persistent DNA 
breaks activate the p53–p21 pathway, which blocks DNA 
replication and cell cycle, thereby inhibiting further genomic 
instability, which is a key event for tumorigenesis. Our study 
further reveals a strong correlation between aneuploidy and 
oncogene activation, implying that p53 has an essential tu-
mor suppressor role in preventing chromosomal abnormality. 
Aneuploidy is characteristic of p53-defi  cient cells and can 
result from a failure of controlling centrosome   duplication, 
which is normally coordinated with other cell cycle events, 
such as DNA replication. Indeed, centromere dysregula-
tion is commonly found in p53-defi  cient cells, but normal 
centrosome duplication can be restored through the re-
introduction of p53 (53). Furthermore, the main control 
mechanism of centromere duplication occurs through the 
CDK2, where the kinase can be inhibited by p21, which is a 
major p53 eff  ector expressed at high levels in Lig4−/− p53p/p 
thymocytes. These observations lead us to further hypoth-
esize that the V(D)J recombination–mediated DNA DSBs 
signal for the activation of p53 and, subsequently, p21. This 
is suffi   cient to inhibit abnormal centromere duplication and 
maintain the  euploidy status of Lig4−/− p53p/p lymphoid 
cells, thereby preventing further genomic instability required 
for tumorigenesis.
Cellular senescence is a state in which cells withdraw 
from the cell cycle, and it has been proposed to be a tumor 
suppression mechanism (26). In human cells, telomere short-
ening is the primary event that causes cells to undergo senes-
cence. Telomere shortening is a result of excessive cellular 
proliferation and DNA replication, culminating in a critical 
state in which the chromosome ends lack the usual  protection. 
It has been proposed that a shortened telomere can be recog-
nized as a broken chromosome, which sends a cellular signal 
evoking the activation of p53. This makes our model useful 
for studying the pathway that leads to cellular senescence and 
its role in suppressing tumorigenesis, as telomere shortening 
does not frequently occur in murine cells because of the extra 
length of their telomeres. Our study further indicates a critical 
role of p21 in inducing cellular senescence to block further 
  genomic instability and tumorigenesis in response to persistent 
DNA DSBs. Other senescent pathways, such as p16–pRB, are 
important in response to diff  erent stimuli.
In addition, cellular senescence, particularly premature 
senescence, has been linked to aging. These Lig4−/− p53p/p 
mice could also be an excellent model for studying the con-
nection between senescence and aging. A compelling fi  nding 
in this regard was that although tumors do not develop in 
Lig4−/− p53p/p mice, they die early of an unknown cause; 
further pathological analyses are required to explore the cause 
of death. One possible cause of death in these animals could 
be premature aging. In support of this, it is well established 
that nonspecifi  c DNA DSBs occur as a result of normal me-
tabolism and environmental exposure and that DNA ligase 
IV plays an important role in the repair of DSBs in general. 
We hypothesize that these nonspecifi  c breaks could accumu-
late in the Lig4−/− background and that the mutant p53 in-
hibits tumorigenesis by inducing senescence, which might 
lead to premature aging and some aging-related diseases.
MATERIALS AND METHODS
Mouse colony and maintenance. Mutant mouse strains (mixed genetic 
background of C57BL/6 and 129SV) and their colony maintenance have 
been previously described (10, 35, 54). Protocols used in this study were ap-
proved by the Institutional Animal Care and Use Committee at the Univer-
sity of Texas M.D. Anderson Cancer Center.
Figure 6.  Proposed model depicting the outcomes of WT or mutant 
p53 activation in response to DNA damage in NHEJ defi  ciency.1460  SENESCENCE SUPPRESSES TUMORIGENESIS | Van Nguyen et al.
Cell senescence assay and immunohistochemistry studies. Acidic 
β-gal activity, which indicates cell senescence, was detected as previously 
described (19). In brief, 6-μm-thick frozen thymic sections from newborn 
mice of diff  erent genotypes were processed for the β-gal assay (staining kit 
was purchased from Cell Signaling Technology). Bone marrow cell suspen-
sion was obtained from 4-mo-old mice, cytospun, and fi  xed with 1:1 ace-
tone/methanol (100% vol/vol). The cells were stained with β-gal and 
observed under a brightfi  eld microscope.
The cells were also stained for the CD19 B cell marker using a standard 
protocol. In brief, after the β-gal assay, the cells were processed for antigen 
retrieval using the proteinase K method, blocked using the streptavidin-
biotin system (Vector Laboratories), and incubated with rat anti-CD19 antibody 
(BD Biosciences) with its corresponding isotype control. The CD19-
positive cells were detected using an anti–rat biotinylated antibody and 
streptavidin–horseradish peroxidase (HRP) (BD).
Thymocytes, thymic sections, and bone marrow cells were stained 
with anti-HP1γ monoclonal antibody (clone 42s2; Millipore), followed by 
HRP/DAB detection system. Thymocytes or thymic sections were also co-
stained with anti-HP1γ and CD25 (BD Biosciences), followed by fl  uores-
cent detection.
LMPCR assays. To detect the signal and coding ends in thymocyte DNA, 
LMPCR assays were performed as previously described (45).
TUNEL assay. A TUNEL assay (DeadEnd Fluorometric TUNEL System; 
Promega) was performed to identify apoptotic cells in thymic sections of 
newborn mice, including a DNase-treated positive control. In brief, frozen 
sections were pretreated with 10 μg/ml proteinase K and equilibrated; DNA 
breaks were labeled with fl  uorescein-12-dUTP. The sections were subse-
quently stained with DAPI (Sigma-Aldrich). The green fl  uorescence of 
apoptotic cells against a blue background (DAPI) was detected by fl  uores-
cence microscopy.
Western blot. Thymocytes were cultured in Dulbecco’s modifi  ed Eagle 
medium supplemented with 10% fetal calf serum and 10 mM Hepes at 
a density of 106 cells/ml. The cells were subsequently exposed to 5 Gy of 
γ-radiation and cultured for 4 h. Whole-cell protein extracts were prepared 
(11) and quantifi  ed by the Bradford method (Bio-Rad Laboratories). Protein 
(50–150 μg/lane) was electrophoretically separated on SDS-PAGE and trans-
ferred to a PVDF membrane. The membranes were blotted with antibodies 
specifi  c for p53, which recognizes p53R172P (CM5; Vector Laboratories), p21 
(C19; Santa Cruz Biotechnology), PUMA (Cell Signaling Technology), 
and β-actin (Sigma-Aldrich). An anti–rabbit or –mouse antibody conjugated 
to HRP was used, and the signal was detected using a chemiluminescence 
kit (PerkinElmer).
Fluorescence in situ hybridization (FISH). For FISH, fetal liver cells 
were obtained from newborn mice of diff  erent genotypes. Metaphase prep-
arations were prepared as previously described (35). Telomeric FISH was 
used to detect chromosomal breaks using a Cy3-labeled protein nucleic acid 
probe (Applied Biosystems).
Online supplemental material. Fig. S1 shows that Lig4−/−p53−/− mice 
are smaller. Fig. S2 shows a TUNEL assay on thymic sections of newborn 
mice. Fig. S3 shows HE staining of thymic sections of newborn mice. Fig. 
S4 shows the SCID phenotype of Lig4−/− p53p/p mice. Fig. S5 shows that 
HP1γ-positive cells are CD25+ thymocytes. Fig. S6 shows that HP1γ-positive 
cells are CD19+ bone marrow cells. Fig. S7 shows sequencing of coding 
ends at the TCR Dδ2 locus. Fig. S8 shows immunohistochemical detection 
of p53 protein on thymic sections from WT and Lig4−/−p53p/p mice. Fig. S9 
shows immunohistochemical detection of p21 protein on thymic sections 
from WT and Lig4−/− p53p/p mice. Fig. S10 shows p16INK4a and β-actin 
protein expression in WT, Lig4+/+p53p/p, and Lig4−/−p53p/p thymocytes. 
Fig. S11 shows phosphorylated retinoblastoma protein expression in WT, 
Lig4+/+p53p/p, and Lig4−/−p53p/p thymocytes. Table S1 shows that p53R172P 
rescues embryonic lethality of Lig4−/− mice. The online version of this article 
is available at http://www.jem.org/cgi/content/full/jem.20062453/DC1.
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